國立虎尾科技大學 |

Antimicrobial Resistance in the 21st Century

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Antimicrobial Resistance in the 21st Century/ edited by I. W. Fong, David Shlaes, Karl Drlica.
其他作者:	Fong, I. W.
面頁冊數:	XVIII, 775 p. 106 illus., 74 illus. in color.online resource. :
Contained By:	Springer Nature eBook
標題:	Immunology. -
電子資源:	https://doi.org/10.1007/978-3-319-78538-7
ISBN:	9783319785387

Antimicrobial Resistance in the 21st Century
Antimicrobial Resistance in the 21st Century[electronic resource] /edited by I. W. Fong, David Shlaes, Karl Drlica. - 2nd ed. 2018. - XVIII, 775 p. 106 illus., 74 illus. in color.online resource. - Emerging Infectious Diseases of the 21st Century. - Emerging Infectious Diseases of the 21st Century.

Chapter1: Introduction : Coordinated Global Action is Needed to Combat Antimicrobial Resistance -- Part I: Examples of Resistance -- Chapter2: Antimicrobial Resistance Among Streptococcus pneumoniae -- Chapter3: Emergence of MRSA in the Community -- Chapter4: Resistance of Gram-negative Bacilli to Antimicrobials -- Chapter5: Drug Resistance in Tuberculosis -- Chapter6: Anaerobic Bacteria: Antimicrobial Susceptibility Testing and Resistance Patterns -- Chapter7: Clinical Significance and Biologic Basis of HIV Drug Resistance -- Chapter8: Resistance of Herpesviruses to Antiviral Agents -- Chapter9: Heteroresistance: A Harbinger of Future Resistance -- Part II: Biology of Resistance -- Chapter10: Epidemiology of Bacterial Resistance -- Chapter11: Transmissible Antibiotic Resistance -- Chapter12: Antibiotics and Resistance in the Environment -- Chapter13: Phenotypic Tolerance and Bacterial Persistence -- Chapter14: Staphylococcus aureus Adaptation During Infection -- Chapter15: Bacterial Signal Transduction Systems in Antimicrobial Resistance -- Chapter16: Fluoroquinolone Interactions with Bacterial Type II Topoisomerases and Target-mediated Drug Resistance -- Part III: Finding New Antimicrobials -- Chapter17: Natural Products in Antibiotic Discovery -- Chapter18: The New vs. Old Target Debate For Drug Discovery -- Chapter19: Non-quinolone Topoisomerase Inhibitors -- Chapter20: Antimicrobial-Mediated Bacterial Suicide -- Chapter21: PK/PD-based Prediction of “Anti-mutant” Antibiotic Exposures Using In Vitro Dynamic Models -- Part IV: Bringing Compounds to Market -- Chapter22: The Role of Pharmacometrics in the Development of Antimicrobial Agents -- Chapter23: New Regulatory Pathways for Antibacterial Drugs -- Chapter24: Economic Incentives for Antibacterial Drug Development: Alternative Market Structures to Promote Innovation.

Antimicrobial resistance is now a general problem. Many of us have elderly relatives who died from a drug-resistant infection, and some of us have suffered from a resistant urinary infection that likely came from intestinal bacteria following antibiotic consumption. Antimicrobial Resistance in the 21st Century provides a broad introduction to the subject in which the situation with problematic pathogens is detailed, the biology of resistance is described, and gaining approval for new antibiotics is discussed. Some topics are immediately practical, such as watching for resistant pathogen sub-populations in cultures taken from patients; other topics point to future research efforts that may lead to new antimicrobials and ways to stimulate the action of existing ones. Overall, Antimicrobial Resistance in the 21st Century provides an update for physicians, serves as a starting point for graduate students interested in solving the resistance problem, and may serve as a text for a course on resistance. Lay readers familiar with microbiology will gain an appreciation for a medical issue that promises to be one of the most important of our time. Ignatius Fong, Department of Medicine, University of Toronto Series Editor – Emerging Infectious Diseases of the 21st Century David Shlaes, Founder, Anti-Infectives Consulting Editor – Antimicrobial Agents and Chemotherapy Karl Drlica, The Public Health Research Institute, New Jersey Medical School, Rutgers, The State University of New Jersey.

ISBN: 9783319785387

Standard No.: 10.1007/978-3-319-78538-7doiSubjects--Topical Terms:

592892
Immunology.

LC Class. No.: QR180-189.5

Dewey Class. No.: 616.079

Antimicrobial Resistance in the 21st Century
LDR:04734nam a22003975i 4500 001 989802
003 DE-He213
005 20200705021958.0
007 cr nn 008mamaa
008 201225s2018 gw | s |||| 0|eng d
020 $a 9783319785387 $9 978-3-319-78538-7
024 7 $a 10.1007/978-3-319-78538-7 $2 doi
035 $a 978-3-319-78538-7
050 4 $a QR180-189.5
072 7 $a MJCM $2 bicssc
072 7 $a MED044000 $2 bisacsh
072 7 $a MJCM $2 thema
082 0 4 $a 616.079 $2 23
245 1 0 $a Antimicrobial Resistance in the 21st Century $h [electronic resource] / $c edited by I. W. Fong, David Shlaes, Karl Drlica.
250 $a 2nd ed. 2018.
264 1 $a Cham : $b Springer International Publishing : $b Imprint: Springer, $c 2018.
300 $a XVIII, 775 p. 106 illus., 74 illus. in color. $b online resource.
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
347 $a text file $b PDF $2 rda
490 1 $a Emerging Infectious Diseases of the 21st Century
505 0 $a Chapter1: Introduction : Coordinated Global Action is Needed to Combat Antimicrobial Resistance -- Part I: Examples of Resistance -- Chapter2: Antimicrobial Resistance Among Streptococcus pneumoniae -- Chapter3: Emergence of MRSA in the Community -- Chapter4: Resistance of Gram-negative Bacilli to Antimicrobials -- Chapter5: Drug Resistance in Tuberculosis -- Chapter6: Anaerobic Bacteria: Antimicrobial Susceptibility Testing and Resistance Patterns -- Chapter7: Clinical Significance and Biologic Basis of HIV Drug Resistance -- Chapter8: Resistance of Herpesviruses to Antiviral Agents -- Chapter9: Heteroresistance: A Harbinger of Future Resistance -- Part II: Biology of Resistance -- Chapter10: Epidemiology of Bacterial Resistance -- Chapter11: Transmissible Antibiotic Resistance -- Chapter12: Antibiotics and Resistance in the Environment -- Chapter13: Phenotypic Tolerance and Bacterial Persistence -- Chapter14: Staphylococcus aureus Adaptation During Infection -- Chapter15: Bacterial Signal Transduction Systems in Antimicrobial Resistance -- Chapter16: Fluoroquinolone Interactions with Bacterial Type II Topoisomerases and Target-mediated Drug Resistance -- Part III: Finding New Antimicrobials -- Chapter17: Natural Products in Antibiotic Discovery -- Chapter18: The New vs. Old Target Debate For Drug Discovery -- Chapter19: Non-quinolone Topoisomerase Inhibitors -- Chapter20: Antimicrobial-Mediated Bacterial Suicide -- Chapter21: PK/PD-based Prediction of “Anti-mutant” Antibiotic Exposures Using In Vitro Dynamic Models -- Part IV: Bringing Compounds to Market -- Chapter22: The Role of Pharmacometrics in the Development of Antimicrobial Agents -- Chapter23: New Regulatory Pathways for Antibacterial Drugs -- Chapter24: Economic Incentives for Antibacterial Drug Development: Alternative Market Structures to Promote Innovation.
520 $a Antimicrobial resistance is now a general problem. Many of us have elderly relatives who died from a drug-resistant infection, and some of us have suffered from a resistant urinary infection that likely came from intestinal bacteria following antibiotic consumption. Antimicrobial Resistance in the 21st Century provides a broad introduction to the subject in which the situation with problematic pathogens is detailed, the biology of resistance is described, and gaining approval for new antibiotics is discussed. Some topics are immediately practical, such as watching for resistant pathogen sub-populations in cultures taken from patients; other topics point to future research efforts that may lead to new antimicrobials and ways to stimulate the action of existing ones. Overall, Antimicrobial Resistance in the 21st Century provides an update for physicians, serves as a starting point for graduate students interested in solving the resistance problem, and may serve as a text for a course on resistance. Lay readers familiar with microbiology will gain an appreciation for a medical issue that promises to be one of the most important of our time. Ignatius Fong, Department of Medicine, University of Toronto Series Editor – Emerging Infectious Diseases of the 21st Century David Shlaes, Founder, Anti-Infectives Consulting Editor – Antimicrobial Agents and Chemotherapy Karl Drlica, The Public Health Research Institute, New Jersey Medical School, Rutgers, The State University of New Jersey.
650 0 $a Immunology. $3 592892
650 0 $a Infectious diseases. $3 1102043
650 0 $a Microbiology. $3 591510
650 0 $a Virology. $3 644995
650 0 $a Epidemiology. $3 635923
650 0 $a Public health. $3 560998
650 2 4 $a Infectious Diseases. $3 668393
650 2 4 $a Public Health. $3 592982
700 1 $a Fong, I. W. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 676893
700 1 $a Shlaes, David. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 1211373
700 1 $a Drlica, Karl. $4 edt $4 http://id.loc.gov/vocabulary/relators/edt $3 676894
710 2 $a SpringerLink (Online service) $3 593884
773 0 $t Springer Nature eBook
776 0 8 $i Printed edition: $z 9783319785370
776 0 8 $i Printed edition: $z 9783319785394
830 0 $a Emerging Infectious Diseases of the 21st Century $3 1281635
856 4 0 $u https://doi.org/10.1007/978-3-319-78538-7
912 $a ZDB-2-SME
912 $a ZDB-2-SXM
950 $a Medicine (SpringerNature-11650)
950 $a Medicine (R0) (SpringerNature-43714)